JP2010540657A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540657A5
JP2010540657A5 JP2010528161A JP2010528161A JP2010540657A5 JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5 JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5
Authority
JP
Japan
Prior art keywords
patient
antigen
antibody
psma
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528161A
Other languages
English (en)
Japanese (ja)
Other versions
JP5951929B2 (ja
JP2010540657A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078742 external-priority patent/WO2009046294A2/en
Publication of JP2010540657A publication Critical patent/JP2010540657A/ja
Publication of JP2010540657A5 publication Critical patent/JP2010540657A5/ja
Application granted granted Critical
Publication of JP5951929B2 publication Critical patent/JP5951929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528161A 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療 Active JP5951929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97736407P 2007-10-03 2007-10-03
US60/977,364 2007-10-03
PCT/US2008/078742 WO2009046294A2 (en) 2007-10-03 2008-10-03 Treatment of proliferative disorders using antibodies to psma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013207386A Division JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Division JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Publications (3)

Publication Number Publication Date
JP2010540657A JP2010540657A (ja) 2010-12-24
JP2010540657A5 true JP2010540657A5 (cg-RX-API-DMAC7.html) 2011-11-24
JP5951929B2 JP5951929B2 (ja) 2016-07-13

Family

ID=40404317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010528161A Active JP5951929B2 (ja) 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Country Status (5)

Country Link
US (4) US20100291113A1 (cg-RX-API-DMAC7.html)
EP (3) EP2209498A2 (cg-RX-API-DMAC7.html)
JP (3) JP5951929B2 (cg-RX-API-DMAC7.html)
CA (1) CA2700410C (cg-RX-API-DMAC7.html)
WO (1) WO2009046294A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
EP2817629A4 (en) * 2012-02-24 2016-01-13 Univ Cornell INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
CA2887047A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
MA41046A (fr) * 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
US20180022819A1 (en) * 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
EP3609544B1 (en) * 2017-04-11 2025-04-09 The Johns Hopkins University Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CA3177330A1 (en) * 2020-05-05 2021-11-11 Aro Biotherapeutics Company Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same
CA3188601A1 (en) 2020-07-08 2022-01-13 LAVA Therapeutics N.V. Antibodies that bind psma and gamma-delta t cell receptors
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
EP4323008A1 (en) 2021-04-14 2024-02-21 ARO Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6197298B1 (en) * 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4140142A1 (de) * 1991-12-05 1993-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim, De Multivalentes dextranreagenz zum einsatz in praezipitationstests
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
EP0628078B1 (en) * 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
JP2001526522A (ja) * 1995-02-24 2001-12-18 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺特異的膜抗原およびその使用
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU6914098A (en) * 1997-04-03 1998-10-30 Universite Laval Transgenic expression in genital tract and sexual accessory glands
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
JP4855577B2 (ja) * 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
CA2369622C (en) * 1999-04-09 2011-06-14 Universitat Zurich Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
AU765588C (en) * 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
HUP0300919A2 (hu) * 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US6375991B1 (en) * 2000-09-08 2002-04-23 Albemarle Corporation Production of concentrated biocidal solutions
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
MXPA03010328A (es) 2001-05-11 2004-02-17 Guilford Pharm Inc Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (en) * 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022995A2 (en) * 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
CA2452288A1 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
PL213948B1 (pl) * 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
EP2048154B2 (en) * 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
WO2003102132A2 (en) * 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
JP2004000045A (ja) * 2002-05-31 2004-01-08 Kyowa Hakko Kogyo Co Ltd 前立腺特異的膜抗原に対する抗体
EP1534331B1 (en) * 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
WO2004088279A2 (en) * 2003-03-28 2004-10-14 Iowa State University Research Foundation, Inc. Allosteric probes and methods
AU2004252170B2 (en) * 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2531595C (en) * 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US9045739B2 (en) * 2004-01-16 2015-06-02 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Immunokinases
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
JP4861308B2 (ja) * 2004-04-07 2012-01-25 ジェネンテック， インコーポレイテッド 抗体結合体の質量分析
US8008442B2 (en) * 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2598454C (en) * 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
DK2298815T3 (en) * 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
EP2207564B1 (en) * 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
EP2240495B1 (en) * 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
RU2523419C2 (ru) * 2008-07-15 2014-07-20 Дженетек, Инк. Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
RU2509968C2 (ru) * 2008-09-08 2014-03-20 Конокофиллипс Компани Система для отделения неконденсируемого компонента на установке для сжижения природного газа
US7897356B2 (en) * 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
CN102308004A (zh) * 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
US20110020327A1 (en) * 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
WO2010073462A1 (ja) * 2008-12-25 2010-07-01 東海ゴム工業株式会社 流体封入式防振装置
CA2759233C (en) * 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011003171A1 (en) * 2009-07-08 2011-01-13 Smart Technologies Ulc Three-dimensional widget manipulation on a multi-touch panel
TWM383852U (en) * 2009-07-13 2010-07-01 Speedtech Corp An improvement of the universal serial bus connector
CN102573925B (zh) * 2009-10-05 2015-08-05 佳能株式会社 光声成像用造影剂和使用所述光声成像用造影剂的光声成像方法

Similar Documents

Publication Publication Date Title
JP2010540657A5 (cg-RX-API-DMAC7.html)
Cai et al. Therapeutic effect of fecal microbiota transplantation on chronic unpredictable mild stress-induced depression
Forte et al. Obesity, diabetes, the cardiorenal syndrome, and risk for cancer
Matavelli et al. (Pro) renin receptor contributes to diabetic nephropathy by enhancing renal inflammation
JP6990170B2 (ja) Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
JP2010515774A5 (cg-RX-API-DMAC7.html)
Zhang et al. Apelin attenuates depressive-like behavior and neuroinflammation in rats co-treated with chronic stress and lipopolysaccharide
JP2008520669A5 (cg-RX-API-DMAC7.html)
JUBIZ et al. Serum thyrotropin and thyroid hormone levels in humans receiving chronic potassium iodide
Paderni et al. Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects
Liu et al. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Tiwari et al. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats
Rabiee et al. Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
Huo et al. Ultrasound‐Guided Capsular Thyroid Injection Therapy With Dexamethasone and Lidocaine Mixture for Subacute Thyroiditis: A Single‐Center Study
Van Dingenen et al. Investigation of orally delivered carbon monoxide for postoperative ileus
JP2010510495A5 (cg-RX-API-DMAC7.html)
Egan et al. A randomized, single-blind, pharmacokinetic and doseresponse study of subcutaneous methotrexate, 15 and 25 MG/week, for refractory ulcerative colitis and Crohn's Disease
CN1921891B (zh) 连接到杯芳烃上的生长因子结合化合物
Thynne et al. A dose of paracetamol for the levothyroxine absorption test
Kodama et al. Four problems with the clinical control of interstitial pneumonia, or chronic fatigue syndrome, using the megadose vitamin C infusion system with dehydroepiandrosterone-cortisol annex
Gupta et al. Evidence based clinical study to assess the usefulness of homoeopathic medicines in patients of benign prostatic hyperplasia
CN115837042B (zh) 当归补血汤在制备增强免疫检查点抑制剂疗效的药物中的应用
Sommer et al. 118 Curing erectile dysfunction—long term effects of taking PDE-5-inhibitors on a daily basis